Moderna eyes late-stage trial for COVID/flu combo shot
Maddie Meyer/Getty Images News

Moderna (NASDAQ:MRNA) said Wednesday it will begin a Phase 3 trial for its combination vaccine against influenza and COVID-19 after the experimental shot, called mRNA-1083, generated positive data in a Phase 1/2 trial.
The ongoing trial is designed to evaluate the messenger-RNA shot against licensed flu vaccines that GSK (GSK) and Sanofi (SNY) market as Fluarix and Fluzone HD, respectively, as well as Modernaâs (MRNA) COVID booster Spikevax.

The randomized, observer-blind study enrolled adults aged 50â79 in two age groups.
Citing interim data, Moderna (MRNA) said that the mRNA-1083 candidate chosen for Phase 3 development led to antibody levels similar to or greater than those generated from the approved flu vaccines.
Its COVID-19-neutralizing antibody levels were similar to the levels generated by the Spikevax booster.
The adverse reactions linked to mRNA-1083 were consistent with findings from the group that received the COVID booster alone.
The company expects to begin a Phase 3 trial for mRNA-1083 in 2023, targeting a potential regulatory nod for the vaccine in 2025.



More on Moderna

Moderna: Now That The COVID Party Is Over, What's Next?
Moderna: Covid Curse
Moving Beyond COVID: A Conservative Options Income Strategy For Moderna
Updated COVID boosters to divide America
Moderna to end mRNA COVID shot production at Lonza plant